KDM3A is not associated with metastasis and prognosis of breast cancer.

Lysine demethylase 3A (KDM3A), also known as JMJD1A, has been associated with metastasis and poor prognosis in several cancer types, including renal cell carcinoma, prostate cancer and Ewing sarcoma. However, little is known regarding the clinicopathological significance of KDM3A expression in breast cancer (BCa). To investigate the clinical relevance of KDM3A expression in the setting of BCa, immunohistochemistry was performed on a tissue microarray consisting of 150 commercially available BCa samples. No significant correlation was identified between KDM3A expression and various clinicopathological variables, including clinical stage, pathological grade, tumor size and the expression statuses of human epidermal growth factor receptor 2, estrogen receptor, and progesterone receptor. In addition, no significant association between KDM3A expression and overall prognosis was observed. Taken together, these findings suggest that there is no significant association between KDM3A expression and clinicopathological variables, indicating that KDM3A may not be associated with the malignant behavior of BCa.